Ethylene

Ethylene

SCHEMBL6503293

C=C.O=C1CCn2c(N3CCN(c4ccc(OCc5ccccc5)cc4)CC3)nc3cccc1c32

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.44
ALDH1A1 P00352 4/20 0.42
HTT P42858 2/20 0.42
KDM4E B2RXH2 2/20 0.42
TSHR P16473 2/20 0.42
HSD17B10 Q99714 1/20 0.42
LMNA P02545 2/20 0.39
MGLL Q99685 1/20 0.39
RAB9A P51151 4/20 0.39
NPC1 O15118 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
ADAMTS4 O75173 1/20 0.38
ADAMTS5 Q9UNA0 1/20 0.38
MAOB P27338 3/20 0.38
MAOA P21397 2/20 0.38
TDP1 Q9NUW8 2/20 0.37
MAPK1 P28482 1/20 0.37
PRKDC P78527 1/20 0.37
GRM5 P41594 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6656878 0.98 ALDH1A1 (0.43) MAPTALDH1A1HTTKDM4ETSHR
SCHEMBL6631403 0.82 MAPT (0.45) MAPTALDH1A1HTTKDM4ETSHR
SCHEMBL6509219 0.81 GAA (0.41) MAPTALDH1A1HTTKDM4ETSHR
Hydrochloric Acid SCHEMBL6505881 0.78 MAPT (0.39) MAPTALDH1A1HTTKDM4ETSHR
SCHEMBL6505984 0.76 PARP1 (0.36) MAPTALDH1A1HTTKDM4ETSHR
SCHEMBL6631361 0.75 HDAC6 (0.46) MAPTALDH1A1HTTKDM4ETSHR
SCHEMBL7262771 0.73 AVPR1A (0.43)
SCHEMBL6503698 0.73 GFER (0.48) MAPTALDH1A1HTTKDM4ELMNA
SCHEMBL6630805 0.71 PARP1 (0.43) ALDH1A1HTTKDM4EHSD17B10TDP1
SCHEMBL6629677 0.71 NPSR1 (0.40) MAPTALDH1A1KDM4EMAPK1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032779-A1 Benzimidazole derivatives, preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2005-02-10 US disclosed
US-6794382-B2 6-OXO-5,6-DIHYDRO-4H-IMIDAZO(4,5,1-IJ)QUINOLINE DERIVATIVES AS INHIBITORS OF ADP-RIBOSYLTRANSFERASE; CARDIOVASCULAR, IMMUNOLOGICAL, RESPIRATORY SYSTEM, AND NEURODEGENERATIVE DISORDER TREATMENT SANOFI-SYNTHELABO (FR) 2004-09-21 US disclosed
US-20030203893-A1 Benzimidazole derivatives, preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2003-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032779-A1 Benzimidazole derivatives, preparation and therapeutic use thereof CBR3, CYP3A7, HDAC7 MAPT 4389/4885ALDH1A1 4006/4885HTT 3164/4885
US-20030203893-A1 Benzimidazole derivatives, preparation and therapeutic use thereof CBR3, HRH4, CBR1 MAPT 4259/4885ALDH1A1 3413/4885HTT 3589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.